AIDS Therapies

New Acyclic Nucleotide As Potent, Less Toxic Than PMEA

Published in AIDS Weekly, June 10th, 1996

A new acyclic nucleotide is just as potent - and, in laboratory studies, nine times less toxic - than adefovir (PMEA).

PMEA [9-(2-phosphonylmethoxyethyl)-adenine] is the prototypic compound for a new class of drugs active against HIV, herpesviruses, and hepatitis viruses. Unlike nucleoside analogs (AZT, ddI, ddC, d4T, etc.), these nucleotide analogs are already in their active form and do not require intracellular processing for activation.

An orally bioavailable form of PMEA, bis-POM-PMEA or adefovir dipivoxil, is being tested for anti-HIV and anti-hepatitis B efficacy in clinical trials.

Now researchers at the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry